Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Brain endothelium
- Neurovascular unit
- BBBNedwork foundation
- Neurovascular unit (molecular inducers)
- Blood brain barrier (BBB) breakdown
- Multiple sclerosis (MS)
- Risk factors that contribute MS
- MS disease course
- Clinical course of MS
- Progression of MS
- MS autopsy protocol
- MS pathology
- Macrophages induce demyelination
- Lesion classification
- Immune cell trafficking across the BBB
- Brain endothelial dysfunction in MS
- Targets for MS drugs
- Treatments: impact on BBB dysfunction
- Fingolimod: limits circulating T-cells
- FTY720-P (Fingolimod: targets S1P receptors)
- Fingolimod improves BBB function: S1P5
- Sphingomyelin cycle more pro-inflammatory
- Acid sphingomyelinase (ASM) - ceramide
- ASM expression in brain endothelial cells
- Endothelial ASM regulates T cell migration
- Brain endothelial ASM regulates T cell migration
- Underlying mechanism?
- ASM and immune cell trafficking
- Natalizumab: antibody against α4 integrins
- Natalizumab (Tysabri): anti-VLA-4 antibody
- Dimethyl fumarate
- MMF reduces BBB inflammation
- MMF improves BBB anti-oxidant capacity
- Conclusions so far
- Mechanisms of BBB failure in MS
- Pathology: reactive astrocytes
- Morphogens and epigenetic regulators?
- RA synthesis in reactive astrocytes
- RA and inflamed blood-brain barrier
- BBB function in health and disease
- microRNAs downregulated in MS BBB
- microRNA-125a and BBB inflammation
- Restoring CNS homeostasis
- Thank you
Topics Covered
- Brain endothelium and the neurovascular unit
- Multiple sclerosis (MS) disease course and pathology
- Blood brain barrier (BBB) breakdown
- Mechanisms of BBB failure in MS
- Gliosis and neurodegeneration
- Irreversible tissue damage through infiltration of immune cells
- Targets for MS drugs
- Treatments and their impact on BBB dysfunction
- Restoring CNS homeostasis
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Vries, E.D. (2018, June 28). The blood-brain barrier in multiple sclerosis: a target for treatment? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 7, 2024, from https://doi.org/10.69645/BOXQ5077.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Dr. Elga de Vries has no commercial/financial relationships to disclose
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I would like to start this Henry Stewart lecture by introducing myself.
My name is Elga de Vries.
I work in the MS center in Amsterdam VU Medical Center.
I've been working on the blood-brain barrier for a long time,
and I have a specific interest in the blood-brain barrier in multiple sclerosis.
Recent insights make me wonder whether this can be a target for treatment.
0:24
So first my disclosures,
just to see that, I have different grants and speaker fees.
A lot of the work that I will be talking about
today is funded by the foundation of MS research.
0:38
So to start off the brain endothelium, as you can see on the left-hand side,
is highly vascularized
and it has a very dense capillary network.
On the right-hand side, when we have an enlargement of a brain capillary,
you can see that in the middle,
there is a capillary lumen,
and that is closed (surrounded) by the endothelial cells.
The endothelial cells are connected to each other by tight junction molecules,
which actually seal off the endothelium,
and make it a continuous layer.
The endothelial cells are ensheathed by a basal lamina that is
formed either by the endothelial cells or by the glial cells,
and so it is called the glial basement membrane.
Furthermore what you can notice in this picture on the right-hand side, is that there
are pericytes that engulf the capillary network as well.
Pericytes are thought to be involved in the regulation of blood flow,
but also they are of high importance for
the development of the blood-brain barrier in ontogeny.
Furthermore what you can see is that
astrocyte endfeet are completely ensheathing the brain capillaries.
So continuous communication between astrocytes and
endothelium makes sure that endothelial cells form a tight blood-brain barrier.
But what you can see at the bottom of this figure, is that
the endothelial cells will express different transporters like Glut-1,
which transport glucose into the brain;
but also so-called ABC transporters,
which are involved in the efflux of unwanted compounds from the endothelial cells;
and thereby protecting the brain.
At the cell-cell contacts,
we find two types of junctions.
We find the adherens junction,
and that is formed by the proteins VE-Cadherin and E-Cadherin;
and we find tight junctions,
so-called Claudin, Claudin 1, 3
and 5 have been described to be present
at the junction of complexes of endothelial cells,
and also Occludin.
Hide